Alzheimer's patients face several hurdles if Biogen's Alzheimer's drug is OK'd

Biogen's experimental Alzheimer's drug, aducanumab, could be a game changer for millions of patients, but the U.S. healthcare system will likely struggle to get it to those who could benefit from it the most, Bloomberg reported May 24.